Do we still need breast cancer screening in the era of targeted therapies and precision medicine?

Insights into Imaging

Table 1 Association of screening and treatment with breast cancer mortality in US women from 2000 to 2012

	Mortality reduction compared to 1975 (%)			Contribution to the difference in mortality reduction in 2012 versus 2000 (%)
	In 2000^a	In 2012^b	Difference	Screening advances	Chemotherapy advances	Hormone therapy advances	Trastuzumab
Overall	37	49	12	17	38	29	15
ER+/HER2−	39	51	12	19	39	42	0
ER+/HER2+	39	58	19	12	22	25	41
ER−/HER2+	29	45	16	11	32	0	57
ER−/HER2−	29	37	8	22	78	0	0

^aRelative to the estimated baseline rate of 64 deaths (model range, 56–73) per 100,000 women in 2000; ^bRelative to the estimated baseline rate of 63 deaths (model range, 54–73) per 100,000 women in 2012. ER oestrogen receptor, HER2 human epidermal growth factor receptor 2. Source: Plevritis et al. [6]